Replies to post #552737 on NorthWest Biotherapeutics Inc (NWBO)

[10baggerz]

Hi Alphapuppy, Merry Christmas (Hanukkah for me)…

Great to see you posting more frequently lately. Your models and clear explanations of GBM as a disease were what convinced me to invest heavily in NWBO in 2020. Previously I’d taken a small position in 2014 after my friend, a GBM DCVAX survivor, told me about the company/clinical trial.

I wanted to get your take on something that I don’t really understand. I’d asked this question to the board previously and only got “Covid” as a possible explanation.

HOW COULD MEDIAN OS IN THE BLINDED/BLENDED 2018 INTERM DATA (23.1 MONTHS) POSSIBLY BE GREATER THAN THE FINAL TREATMENT ARM MOS DATA (22.4 MONTHS) 2 YEARS LATER?

One would think that mOS would have been substantially greater in the treatment arm (even considering that many of the control arm patients were crossovers that got DCVAX). In fact, many here were predicting 26-28 months for mOS in the treatment arm.

Notes: For consistency using mOS from SURGERY rather than from RANDOMIZATION.
Also, don’t get me wrong, I’m confident the data is more than good enough to gain approval and I’m not trying to sow any doubt.

SOURCES:

https://nwbio.com/updated-interim-data-from-phase-3-trial-of-dcvax-l-for-glioblastoma/

https://nwbio.com/northwest-biotherapeutics-reports-positive-top-line-results-from-phase-3-trial-of-dcvax-l-for-glioblastoma/